Mevalone Label Extension in France

Eden Biosolutions

07/01/2026 07:00

RNS Number : 8973N

Eden Research plc

07 January 2026

 

As the information in this release pertains to EDEN RESEARCH PLC, this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. The information is disclosed in accordance with the Company's obligations under Article 17 of the UK MAR. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

7 January 2026

 

 

Eden Research Plc

("Eden" or "Company")

 

Mevalone Label Extension in France

 

Mevalone® approved in France for use on grapes against downy and powdery mildew

 

Eden Research plc (AIM: EDEN), a leader in sustainable biopesticide and biocontrol technologies, is pleased to announce that Mevalone has been granted approval by the French authorities for use on grapes to control downy and powdery mildew, subject to customary restrictions. 

 

France is one of the world's largest and most affected markets for grape downy mildew, and this is driving steady demand for conventional fungicides, biopesticides, and resistant varieties across its more-than 780,000 hectares of vines. Climate‑driven increases in mildew pressure, regulatory pressure on copper and synthetic chemistry, and growth in organic viticulture are reshaping the structure and dynamics of this market.

 

Biopesticides are a fast‑growing segment of the French crop protection market: the French biopesticides sector is estimated at more than USD 200 million in 2025 and is projected to grow strongly to 2030, with grapes representing a key market segment because of heavy pressure from downy mildew, powdery mildew and botrytis and the challenging regulatory restrictions placed on pesticides in general.

 

Downy mildew has become one of the most damaging diseases in French vineyards with recent years (2023-2024) seeing severe outbreaks in Bordeaux and many other regions, cutting local harvests by up to a fifth or more.

 

While any estimate is subject to ever-evolving regulatory and commercial circumstances, the Company currently estimates that the potential peak revenue for this opportunity (with its current label extension conditions on the timing of applications) to be in the region of up to €8 million per annum. Given the timing of receipt of this label extension for two new diseases and the industry's schedule for marketing and stocking products for the growing season, the Company is not changing its market guidance at this stage but will monitor this as the season develops.

 

 

Sean Smith, CEO of Eden Research, commented:

 

"With France recently having tightened rules on copper fungicides, revoking approval for many formulations and leaving only a small number of authorised copper products under stricter conditions, the approval of this label extension for Mevalone is timely, creating a significant opportunity for Eden in the coming years. 

 

In addition, organic vineyard area has continued to increase with approximately one-fifth of French vineyard land now farmed organically, exceeding the national agricultural average and reinforcing demand for alternative solutions such as Mevalone, which is already certified as organic."

 

 

 

 

For further information contact:

 

Eden Research plc
www.edenresearch.com
Sean Smith
 Alex Abrey
01285 359 555
Cavendish Capital Markets Limited (Nominated advisor and joint broker)
Giles Balleny / Elysia Bough (Corporate Finance)
Harriet Ward (Corporate Broking)
 Dale Bellis (Sales)
020 7220 0500
Oberon Capital (Joint Broker)
020 3179 5300
Nick Lovering
Mike Seabrook
Adam Pollock
Hawthorn Advisors (Financial PR)
Victoria Ainsworth
eden@hawthornadvisors.com

 

 

 

 

Notes to Editors:

 

Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.

 

Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden has three products currently on the market:

 

Based on plant-derived active ingredients, Mevalone® is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops.  It is a useful tool in crop defence programmes and is aligned with the requirements of integrated pest management programmes. It is approved for sale in a number of key countries whilst Eden and its partners pursue regulatory clearance in new territories thereby growing Eden's addressable market globally.

 

Cedroz™ is a bionematicide that targets free living nematodes which are parasitic worms that affect a wide range of high-value fruit and vegetable crops globally.  Cedroz is registered for sale on two continents and Eden's commercial collaborator, Eastman Chemical, is pursuing registration and commercialisation of this important new product in numerous countries globally.

 

Eden's seed treatment product, EcovelexÔ was developed to safely tackle crop destruction caused by birds - a major cause of losses in maize and other crops. Ecovelex works by creating an unpleasant taste or odour that repels birds, leaving the seeds safely intact and the birds unaffected and free to find alternative food sources. The product is based on Eden's plant-derived chemistry, registered in the EU, U.S. and elsewhere, and formulated using Eden's Sustaine® microencapsulation system.

 

Eden's Sustaine® encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. Sustaine microcapsules are naturally-derived, plastic-free, biodegradable micro-spheres derived from yeast. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN. It was awarded the London Stock Exchange Green Economy Mark in January 2021, which recognises London-listed companies that derive over 50% of their total annual revenue from products and services that contribute to the global green economy. Eden derives 100% of its total annual revenues from sustainable products and services.

 

For more information about Eden, please visit:  www.edenresearch.com.

 

Follow Eden on LinkedIn, Twitter and YouTube. 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
REAUNRRRNAUARUR